A new anti-AIDS drug produced by Zhongyu New Drugs and Wuxi Pharmaceutical Co., Ltd. was approved for marketing in the United States. This is also the first case of sterile biological agents produced in China and approved in the United States.
The new drug Trogarzo is a new type of antiretroviral drug. It is also the first long-acting new anti-AIDS drug. Unlike conventional treatments, it is only required to be administered intravenously every 14 days.
Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options.
Efficacy of Trogarzo was demonstrated in a single arm, multicenter clinical trial of heavily treatment-experienced HIV-infected subjects with multidrug resistant HIV-1.
With the reform of the review and approving system for drug approval in China and the related supporting policies, this innovative drug is also actively planning to be supplied to the home market so as to benefit more domestic patients.
The FDA has approved Trogarz, a human immunodeficiency virus type 1 or HIV-1 antiretroviral drug, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. The approved recommended dosage of Trogarzo is a single intravenous loading dose of 2,000 mg followed by a maintenance IV dose of 800 mg every two weeks. Trogarzo is administered after dilution in 250 ml of 0.9 percent sodium chloride injection, USP.
(Source: Jiangsu International Channel)
